Results 1 to 10 of about 43,476 (151)

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors [PDF]

Journal of Pharmacological Sciences, 2015
Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters
Kentaro Minami, Yoshinari Shinsato, Masatatsu Yamamoto, Homare Takahashi, Shaoxuan Zhang, Yukihiko Nishizawa, Sho Tabata, Ryuji Ikeda, Kohich Kawahara, Kazutake Tsujikawa, Kazuo Chijiiwa, Katsushi Yamada, Shin-ichi Akiyama, Sandra Pérez-Torras, Marcal Pastor-Anglada, Tatsuhiko Furukawa, Takeda Yasuo   +16 more
doaj   +8 more sources

Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma [PDF]

Oncology Research
Cholangiocarcinoma (CCA) is an aggressive cancer originating from bile duct epithelium. Surgical resection remains the primary curative treatment for CCA. However, most CCA patients are diagnosed at an advanced stage, which limits the applicability of surgical resection. Gemcitabine is widely used as a first-line chemotherapeutic agent for unresectable
Kidoikhammouan, Sonexai, Saengboonmee, Charupong, Wongkham, Sopit, Seubwai, Wunchana   +3 more
openaire   +3 more sources

Insights into gemcitabine resistance and the potential for therapeutic monitoring [PDF]

Metabolomics, 2018
Gemcitabine is an important component of pancreatic cancer clinical management. Unfortunately, acquired gemcitabine resistance is widespread and there are limitations to predicting and monitoring therapeutic outcomes.To investigate the potential of metabolomics to differentiate pancreatic cancer cells that develops resistance or respond to gemcitabine ...
Teklab Gebregiworgis, Fatema Bhinderwala, Vinee Purohit   +2 more
exaly   +3 more sources

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer [PDF]

International Journal of Molecular Sciences, 2021
The overall five-year survival rate of pancreatic cancer has hardly changed in the past few decades (less than 10%) because of resistance to all known therapies, including chemotherapeutic drugs. In the past few decades, gemcitabine has been at the forefront of treatment for pancreatic ductal adenocarcinoma, but more strategies to combat drug ...
Jin Xu, Zhen Tan, Jiang Liu
exaly   +3 more sources

Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer [PDF]

FASEB BioAdvances
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer‐related mortality, characterized by intrinsic resistance to conventional therapies and limited effective treatment options. In this study, we investigated the role of the CXCR2
Caitlin Molczyk, Reegan Sturgeon, Sugandha Saxena, Esther Johnson, Rakesh Bhatia, Namita Bhyravbhatla, Sushil Kumar, Surinder K. Batra, Rakesh K. Singh   +8 more
doaj   +2 more sources

Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer [PDF]

Biomolecules
Oral microbiota have been implicated in pancreatic ductal adenocarcinoma (PDAC) and may contribute to chemotherapy resistance. While previous studies attributed bacteria-induced resistance to indirect host modulation, recent findings suggest a direct ...
Geng Xu, Yaling Jiang, Chen Sun, Bernd W. Brandt, Kamran Nazmi, Luca Morelli, Giulia Lencioni, Elisa Giovannetti, Dongmei Deng   +8 more
doaj   +2 more sources

Integrated transcriptomic analysis identifies lactylation-linked gemcitabine resistance and therapeutic targets in intrahepatic cholangiocarcinoma [PDF]

Frontiers in Cell and Developmental Biology
BackgroundIntrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy of the bile ducts, and resistance to gemcitabine, a first-line chemotherapy, significantly complicates treatment.
Wenwei Xie, Wenwei Xie, Jialiang Hu, Jialiang Hu, Hanmei Xu, Hanmei Xu   +5 more
doaj   +2 more sources

The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability [PDF]

Cell Death and Disease
Gemcitabine resistance is a major clinical challenge in pancreatic cancer (PC); therefore, strategies to combat gemcitabine resistance are urgently required. Reprogramming pyrimidine metabolism by oncogenic signaling contributes to cancer progression and
Wenming Zhang, Rui Liu, Junwen Hu, Shuangyan Wan, Yeqin Zou, Tong Che, Jin Zhang, Leifeng Chen, Xiaogang Peng   +8 more
doaj   +2 more sources

CSN6 Promotes Pancreatic Cancer Progression and Gemcitabine Resistance via Antagonizing DCAF1‐Mediated Ubiquitination of NPM1 [PDF]

Advanced Science
Pancreatic ductal adenocarcinoma (PDAC) is a fatal cancer with poor prognosis. COP9 signalosome subunit 6 (CSN6), a key regulator of different E3 ubiquitin ligases, plays oncogenic roles in various cancers.
Yijing Zhang, Han Gao, Aiwen Tang, Haiwen Lyu, Zongmin Fan, Jiahui Guo, Yuzhi Wang, Hairong Yi, Qihao Pan, Haidan Luo, Baifu Qin, Boyu Zhang, Xiangqi Meng, Qingxin Liu, Mong‐Hong Lee   +14 more
doaj   +2 more sources

Promising molecular mechanisms responsible for gemcitabine resistance in cancer

Genes and Diseases, 2015
Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma (PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good initial response to gemcitabine-based chemotherapy but would eventually develop resistance.
Yanfei Jia, Jingwu Xie
exaly   +3 more sources